CureMatch Gets Bridge Funding For Personalized Medicine Efforts

San Diego-based CureMatch, a startup focused on personalimzed medicine and combination therapy in the oncology market, says it has raised a bridge round to its Series A financing. Size of the funding was not announced. The funding came from Serra Ventures and angel Phil Trubey (founder of Websense). CureMatch says it provides a data-driven report that scores combinations of cancer drugs that are tailored for individual patients. Blaise Barrelet is CEO of CureMatch. The funding was led by Steve Beck, Managing Partner at Serra Venture's San Diego office. CureMatch says it is talking to additional investors about its Series A funding.